IL-1RAP CAR T have been proposed for a first phase I clinical trial in CML patients (NCT02842320, Study Details | Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML) | ClinicalTrials.gov//clinicaltrials.gov/study/NCT02842320 accessed on 19 December 2023) and AML patients (NCT04169022, Search for: Other terms: NCT04169022 | Card Results | ClinicalTrials.gov /www.clinicaltrials.gov/search?term=NCT04169022, accessed on 19 December 2023) [12,79,80]. Here, IL1RAP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.